These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 29371619)

  • 41. Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    An SJ; Scaria PV; Chen B; Barnafo E; Muratova O; Anderson C; Lambert L; Chae MH; Yang JS; Duffy PE
    Vaccine; 2018 May; 36(21):2978-2984. PubMed ID: 29681410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Markedly enhanced immunogenicity of a Pfs25 DNA-based malaria transmission-blocking vaccine by in vivo electroporation.
    LeBlanc R; Vasquez Y; Hannaman D; Kumar N
    Vaccine; 2008 Jan; 26(2):185-92. PubMed ID: 18054817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-Pfs25 human plasma reduces transmission of Plasmodium falciparum isolates that have diverse genetic backgrounds.
    Da DF; Dixit S; Sattabonkot J; Mu J; Abate L; Ramineni B; Ouedraogo JB; MacDonald NJ; Fay MP; Su XZ; Cohuet A; Wu Y
    Infect Immun; 2013 Jun; 81(6):1984-9. PubMed ID: 23509152
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Luo K; Zavala F; Gordy J; Zhang H; Markham RB
    Vaccine; 2017 Apr; 35(18):2358-2364. PubMed ID: 28342669
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
    Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
    Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Plasmodium berghei HAP2 induces strong malaria transmission-blocking immunity in vivo and in vitro.
    Blagborough AM; Sinden RE
    Vaccine; 2009 Aug; 27(38):5187-94. PubMed ID: 19596419
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
    Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sterile protection and transmission blockade by a multistage anti-malarial vaccine in the pre-clinical study.
    Iyori M; Blagborough AM; Mizuno T; Abe YI; Nagaoka M; Hori N; Yamagoshi I; Da DF; Gregory WF; Hasyim AA; Yamamoto Y; Sakamoto A; Yoshida K; Mizukami H; Shida H; Yoshida S
    Front Immunol; 2022; 13():1005476. PubMed ID: 36248835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Heterologous prime-boost regimen adenovector 35-circumsporozoite protein vaccine/recombinant Bacillus Calmette-Guérin expressing the Plasmodium falciparum circumsporozoite induces enhanced long-term memory immunity in BALB/c mice.
    Arama C; Assefaw-Redda Y; Rodriguez A; Fernández C; Corradin G; Kaufmann SH; Reece ST; Troye-Blomberg M
    Vaccine; 2012 Jun; 30(27):4040-5. PubMed ID: 22521849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density.
    Sherrard-Smith E; Sala KA; Betancourt M; Upton LM; Angrisano F; Morin MJ; Ghani AC; Churcher TS; Blagborough AM
    Elife; 2018 Jun; 7():. PubMed ID: 29914622
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of anti-malarial transmission blocking immunity with a recombinant ookinete surface antigen of Plasmodium berghei produced in silkworm larvae using the baculovirus expression vector system.
    Matsuoka H; Kobayashi J; Barker GC; Miura K; Chinzei Y; Miyajima S; Ishii A; Sinden RE
    Vaccine; 1996 Feb; 14(2):120-6. PubMed ID: 8852407
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of full-length Plasmodium falciparum P48/45 in P. berghei blood stages: A method to express and evaluate vaccine antigens.
    Othman AS; Lin JW; Franke-Fayard BM; Kroeze H; van Pul FJA; Chevalley-Maurel S; Ramesar J; Marin-Mogollon C; Jore MM; Morin MJ; Long CA; Sauerwein R; Birkett A; Miura K; Janse CJ; Khan SM
    Mol Biochem Parasitol; 2018 Sep; 224():44-49. PubMed ID: 30053393
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intranasal administration of the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei with the modified heat-labile toxin of Escherichia coli (LTK63) induces a complete protection against malaria challenge.
    Romero JF; Ciabattini A; Guillaume P; Frank G; Ruggiero P; Pettini E; Del Giudice G; Medaglini D; Corradin G
    Vaccine; 2009 Feb; 27(8):1266-71. PubMed ID: 19111883
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional Conservation of P48/45 Proteins in the Transmission Stages of
    Cao Y; Hart RJ; Bansal GP; Kumar N
    mBio; 2018 Sep; 9(5):. PubMed ID: 30181253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL; Rowe C; Reiter K; Chen B; Nguyen V; Aebig J; Rausch KM; Kumar K; Wu Y; Jin AJ; Jones DS; Narum DL
    Vaccine; 2013 Jun; 31(28):2954-62. PubMed ID: 23623858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.